<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Following reports that <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> (AA) blocks <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptors, we examined its possible neuroprotective properties in vivo (gerbil bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> model: BCAO) and in vitro (<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced <z:chebi fb="40" ids="18243">dopamine</z:chebi> (<z:mp ids='MP_0000273'>DA</z:mp>) release in brain slices) </plain></SENT>
<SENT sid="1" pm="."><plain>Five minutes of BCAO caused substantial cell loss of 90-95% and 40-50% in gerbil CA1 hippocampus and striatum, respectively, measured in <z:chebi fb="1" ids="51686">haematoxylin</z:chebi> and eosin-stained sections, 5 days post-insult </plain></SENT>
<SENT sid="2" pm="."><plain>AA (500 mg kg(-1) day(-1) i.p. for 312 days, first dose 1 h before occlusion) significantly (P&lt;0.05) reduced striatal cell loss (from 40 to 13%) while only reducing CA1 cell loss from 95 to 88% </plain></SENT>
<SENT sid="3" pm="."><plain>A lower dose (250 mg kg(-1) day(-1) i.p. for 312 days) was ineffective in either region </plain></SENT>
<SENT sid="4" pm="."><plain>AA (750 mg kg(-1) day(-1) i.p. for 312 days) caused significant striatal protection (cell loss reduced from 49 to 20%) if treatment was initiated 1 h before occlusion </plain></SENT>
<SENT sid="5" pm="."><plain>Initiation of treatment immediately post occlusion did not cause significant protection </plain></SENT>
<SENT sid="6" pm="."><plain>Neither treatment regime protected CA1 hippocampus </plain></SENT>
<SENT sid="7" pm="."><plain>In separate experiments we examined the effect of AA on <z:mp ids='MP_0000273'>DA</z:mp> release, monitored by voltammetry, in an in vitro model of striatal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Four <z:mp ids='MP_0000273'>DA</z:mp> release variables were measured: T(on)--time from initiation of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> to the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:mp ids='MP_0000273'>DA</z:mp> release, T(pk)--the time from <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:mp ids='MP_0000273'>DA</z:mp> release to maximum, deltaDA/deltat--the mean rate of <z:mp ids='MP_0000273'>DA</z:mp> release and [<z:mp ids='MP_0000273'>DA</z:mp>](max)-- the maximum extracellular <z:mp ids='MP_0000273'>DA</z:mp> concentration </plain></SENT>
<SENT sid="9" pm="."><plain>Control values in drug-naive slices were: T(on)=193+/-8 s, T(pk) = 24 +/- 4 s, [<z:mp ids='MP_0000273'>DA</z:mp>](max) = 69 +/- 6 microM and deltaDA/deltat = 4.2 +/- 0.7 microM s(-1) (means+/-S.E.M., n=15) </plain></SENT>
<SENT sid="10" pm="."><plain>212 h pretreatment with AA (0.4 to 10 mM) did not affect T(on) or [<z:mp ids='MP_0000273'>DA</z:mp>](max) but increased T(pk) and decreased deltaDA/deltat (P&lt;0.05) with an EC50 of 1.66 mM </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="31882">NMDA</z:chebi> (100 microM) shortened T(on) </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="44485">N-ethylmaleimide</z:chebi> (20 microM) had no effect on the response to AA but potentiated the action of <z:chebi fb="0" ids="31882">NMDA</z:chebi> on T(on) </plain></SENT>
<SENT sid="13" pm="."><plain>AA (2 or 10 mM) had no effect on the response to <z:chebi fb="0" ids="31882">NMDA</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>We conclude that AA is neuroprotective against global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in the striatum and that some of this action may be due to attenuation of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced <z:mp ids='MP_0000273'>DA</z:mp> release </plain></SENT>
<SENT sid="15" pm="."><plain>This action is mediated neither by blockade of the <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor nor modulation of its redox status </plain></SENT>
</text></document>